Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals reported results from its 2026 annual stockholder meeting. Stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares of common stock, respectively, for future equity grants and purchases.
All three director nominees were elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation as described in the proxy statement and ratified Ernst & Young LLP as Rigel’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Wasman Jane reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Jane Wasman received an equity grant of 5,750 shares of Common Stock. The award is structured as Restricted Stock Units that will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues serving on the Board of Directors.
Following this grant, her direct holdings increase to 18,250 shares, reflecting routine, compensation-related equity rather than an open-market stock purchase.
RIGEL PHARMACEUTICALS INC director Walter H. Moos received an equity award. On 2026-05-15, he was granted 5,750 shares of Common Stock at a grant price of $0.00 per share through a Restricted Stock Unit (RSU) award.
The footnote states these shares will be acquired only when the RSUs fully vest on the date prior to the company’s next Annual Meeting, as long as he continues serving on the Board of Directors. After this award, his direct holdings are 18,472 Common Stock shares.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Michael Patrick Miller reported an equity grant of 5,750 shares of Common Stock via Restricted Stock Units. The award has a grant price of $0.00 per share because it is a compensation grant, not a market purchase.
According to the footnote, these Restricted Stock Units will fully vest on the date prior to the company’s next Annual Meeting, as long as Miller continues serving on the Board of Directors. After this grant, he holds 5,937 shares of Common Stock directly.
LAPOINTE ANTHONY GREGG reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Anthony Gregg Lapointe reported an equity compensation grant of 5,750 shares of Common Stock, recorded at a price of $0.00 per share. These shares are tied to a Restricted Stock Unit award that will fully vest on the date prior to the company’s next Annual Meeting, if he continues serving on the Board of Directors. Following this award, Lapointe’s reported direct holdings total 18,250 shares of Common Stock.
RIGEL PHARMACEUTICALS INC director Alison L. Hannah received an equity award in the form of Restricted Stock Units. The filing shows a grant of 5,750 shares of Common Stock at a price of $0.00 per share, reflecting a compensation-related award rather than a market purchase.
These shares are to be acquired upon vesting of the Restricted Stock Unit award. According to the terms, the units will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues to serve on the Board of Directors. After this grant, her direct Common Stock holdings reported in this filing total 16,375 shares.
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Kamil Ali-Jackson received a stock grant tied to board service. The Form 4 shows an award of 5,750 shares of Common Stock at no cash cost, delivered as Restricted Stock Units. These units will fully vest on the date prior to the company’s next Annual Meeting, as long as the director continues serving on the Board. After this grant, the director holds 15,125 shares of Common Stock directly.
Rigel Pharmaceuticals reports that Armistice Capital, LLC and Steven Boyd jointly hold 1,280,000 shares of Common Stock, representing 6.93% of the class as of 03/31/2026. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement, and the Master Fund is the direct holder. The statement is a Schedule 13G joint filing signed on 05/15/2026.